Clinical trials: EBV
EBV Infections, Kidney Transplant
Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors
This clinical study will evaluate the safety and tolerability of an IDO-1 inhibitor in patients receiving a kidney transplant. The study includes individuals who have not previously been infected with Epstein-Barr virus (EBV) and…
- Trial name
- IDEP (NCT07368153)
- Testing
- indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor
- Where
- 4 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- University Hospital, Basel, Switzerland
Pathogen Infection, EBV Infection
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients.
- Conditions
- Pathogen Infection, EBV Infection, CMV Infection, Adenovirus Infection
- Trial name
- NCT03159364
- Testing
- pathogen-specific CTLs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
ME/CFS, ME/CFS Following EBV-associated Infectious Mononucleosis
ME/CFS Brain Fog: Cognitive Rehabilitation Trial
The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog.
- Conditions
- ME/CFS, ME/CFS Following EBV-associated Infectious Mononucleosis, ME/CFS Following COVID-19, Chronic Fatigue
- Trial name
- NCT07523113
- Testing
- Processing Speed Training, In-session Instrumental Activities of Daily Living Training, Transfer Package
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
EBV, Epstein-Barr Virus Infection
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults
Background: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Up to 1 in 10 people who get mono can have fatigue that lasts more than 6 months. One out of 100 people can have severe complications.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis
- Trial name
- NCT04645147
- Testing
- EBV gp350-Ferritin Vaccine
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
EBV-DNA Viremia
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
- Trial name
- NCT07438067
- Testing
- EBV-AST cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Daihong Liu
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
- Conditions
- Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- Trial name
- NCT04554914
- Testing
- Tabelecleucel
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 190 people
- Sponsor
- Pierre Fabre Medicament
EBV Infection After Allogenic HSCT
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell…
- Trial name
- NCT07693881
- Testing
- Rituximab (R)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
- Trial name
- NCT07703657
- Testing
- Rituximab (Arm A), Standard Post-Transplant Supportive Care
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Yang Donglin
BKV Infection, CMV Infection
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic…
- Conditions
- BKV Infection, CMV Infection, EBV Infection
- Trial name
- NCT07685457
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- LucasBio
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and…
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm
- Trial name
- NCT06741072
- Testing
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
BKV Infection, EBV Infection
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after…
- Conditions
- BKV Infection, EBV Infection, CMV Infection
- Trial name
- NCT07670468
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- LucasBio
EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment…
- Conditions
- EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma
- Trial name
- CILESTE (NCT04664179)
- Testing
- Dose Level 1A: 2 x 10^7 cells/m2, Dose Level 2A: 6 x 10^7 cells/m2, Dose Level 2B: 6 x 10^7 cells/m2
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Baylor College of Medicine
EBV
Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis
This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology.
- Trial name
- DIAGEPS (NCT03650231)
- Testing
- Serological giagnosis
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Epstein-Barr Virus (EBV), Healthy Volunteers
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.
- Trial name
- NCT07536048
- Testing
- Investigational Procedure
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
T-cell Lymphoma, NK-Cell Lymphoma
A Registry for People With T-cell Lymphoma
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT05978141
- Testing
- Optional Blood Sample and Nail Sample
- Where
- 26 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a…
- Conditions
- Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT05507541
- Testing
- Biospecimen Collection, Computed Tomography, Ontorpacept
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Relapsed or Refractory EBV-associated Hematological Malignancies
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in the treatment of relapsed or refractory EBV-associated hematological malignancies,to preliminarily explore the clinical efficacy ,evaluate the…
- Trial name
- NCT07532746
- Testing
- KSD-101
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Kousai Bio Co., Ltd.
EBV Associated Lymphoid Neoplasms
KSD-101 in Patients With EBV-associated Hematological Malignancies
Epstein-Barr virus (EBV) is a double-stranded DNA virus belonging to the Gammaherpesvirinae subfamily of Herpesviridae. It primarily infects B cells and pharyngeal epithelial cells, and can also infect NK cells and T cells.
- Trial name
- NCT07525024
- Testing
- Autologous dendritic cell vaccine
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Ruijin Hospital
EBV-associated Haematologic Neoplasms
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
The primary objectives of this study is to evaluate the tolerability and safety of KSD-101 in Patients with EBV-associated haematologic neoplasms, observe the dose-limiting toxicity (DLT) and and to explore the maximum tolerated…
- Trial name
- NCT05635591
- Testing
- Autologous monocyte - derived DCs pulsed with EBV antigen
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Tongji Hospital
EBV Infection After Allogenic HSCT
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.
- Trial name
- NCT06119256
- Testing
- EBV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chinese PLA General Hospital